FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Glaxo Group Limited
Glaxo Group Limited A Corporation

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Glaxo Group Limited patents


      
Recent patent applications related to Glaxo Group Limited. Glaxo Group Limited is listed as an Agent/Assignee. Note: Glaxo Group Limited may have other listings under different names/spellings. We're not affiliated with Glaxo Group Limited, we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Glaxo Group Limited-related inventors



Search recent Press Releases: Glaxo Group Limited-related press releases
Count Application # Date Glaxo Group Limited patents (updated weekly) - BOOKMARK this page
12014028813309/25/143 -amino- pyrazole derivatives useful against tuberculosis
22014022725908/14/14Modified proteins and peptides
32014022726408/14/14Drug fusions and conjugates with extended half life
42014020560407/24/14Antigen binding constructs
52014020566107/24/14Formulation for retinoid-containing soft gelatin capsules
62014020021807/17/14Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
72014019340707/10/14Drug fusions and conjugates
82014018775007/03/14Methods for selecting protease resistant polypeptides
92014017971506/26/142,3-dihydroimidazo[1 ,2-c] pyrimidin-5(1 h)-one compounds use as lp-pla2 inhibitors
102014015870406/12/14Medicament dispenser
112014014099605/22/14Anti-serum albumin biding variable domains
122014014099605/22/14Anti-serum albumin biding variable domains
132014011643405/01/14Dry powder inhaler compositions
142014011643405/01/14Dry powder inhaler compositions
152014011292904/24/14Tumour necrosis factor receptor 1 antagonists
162014011388804/24/14Novel combination of therapeutic agents
172014011392204/24/14Compounds
182014011292904/24/14Tumour necrosis factor receptor 1 antagonists
192014011388804/24/14Novel combination of therapeutic agents
202014011392204/24/14Compounds
212014010589404/17/14Humanized anti-il-18 antibodies
222014010591504/17/14Bcma (cd269/tnfrsf17) - binding proteins
232014010589404/17/14Humanized anti-il-18 antibodies
242014010591504/17/14Bcma (cd269/tnfrsf17) - binding proteins
252014007631403/20/14Manifold for use in medicament dispenser
262014008086303/20/14Muscarinic acetylcholine receptor antagonists
272014007631403/20/14Manifold for use in medicament dispenser
282014008086303/20/14Muscarinic acetylcholine receptor antagonists
292014005690002/27/14Method for inhibiting binding to b-cell receptor
302014005810502/27/14Substituted diketopiperazines and their use as oxytocin antagonists
312014005071902/20/14Antibodies
322014005172002/20/14N-cyclobutyl - imidazopyridine - methylamine as trpv1 antagonists
332014003898902/06/14Tetrahydropyrazolo [1,5-a] pyrimidine as anti-tuberculosis compounds
342014002359601/23/14Novel composition
352014002455801/23/14Method of treatment
362014000517701/02/14Pyridinyl- and pyrazinyl-methyloxy-aryl derivatives useful as inhibitors of spleen tyrosine kinase (syk)
372014000518801/02/14Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
382013034546512/26/13Process for the preparation of retigabine
392013033698912/19/13Methods of identifying a patient population
402013031590111/28/13Novel uses
412013031704111/28/13Compounds
422013031028111/21/13Novel antigen binding proteins
432013030233511/14/13Ligands that bind tgf-beta receptor ii
442013026771710/10/13Process for the preparation of atovaquone
452013026118510/03/13Benzamide derivatives as ep4 receptor agonists
462013025172409/26/13Antigen binding proteins to oncostatin m (osm)
472013025318809/26/13Novel compounds
482013023750109/12/13Benzofuran compounds for the treatment of hepatitis c virus infections
492013022420408/29/13Method of treatment based on atad2 inhibitors
502013022420408/29/13Method of treatment based on atad2 inhibitors
512013021315408/22/13Method of determining cleanliness
522013021339408/22/13Dispensing device
532013021765808/22/13Pyrazole compounds acting against allergic, inflammatory and immune disorders
542013021315408/22/13Method of determining cleanliness
552013021339408/22/13Dispensing device
562013021765808/22/13Pyrazole compounds acting against allergic, inflammatory and immune disorders
572013021089208/15/13Method of treatment
582013021089208/15/13Method of treatment
592013020370508/08/13Pyrazole compounds acting against allergic, immune and inflammatory conditions
602013020380208/08/133 -amino- pyrazole derivatives useful against tuberculosis
612013020370508/08/13Pyrazole compounds acting against allergic, immune and inflammatory conditions
622013020380208/08/133 -amino- pyrazole derivatives useful against tuberculosis
632013019641208/01/13Magi polynucleotides, polypetides, and antibodies
642013019641208/01/13Magi polynucleotides, polypetides, and antibodies
652013018925507/25/13Fusions and conjugates of insulinotropic agents
662013018925507/25/13Fusions and conjugates of insulinotropic agents
672013013133805/23/13Substituted diketopiperazines as oxytocin antagonists
682013013133805/23/13Substituted diketopiperazines as oxytocin antagonists
692013011813205/16/13Machine and method for pharmaceutical and pharmaceutical-like product assembly
702013011813205/16/13Machine and method for pharmaceutical and pharmaceutical-like product assembly
712013010969005/02/13Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
722013010969005/02/13Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
732013010278304/25/13Substituted diketopiperazines and their use as oxytocin antagonists
742013007819803/28/13Novel use
752013005337502/28/13Amino-quinolines as kinase inhibitors
762013003947002/14/13Sample plate for an x-ray powder diffraction apparatus
772013004098402/14/137-(lh-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors
782013003001201/31/13Compounds
792013003001501/31/13Muscarinic acetylcholine receptor antagonists
802013002354101/24/13Voltage-gated sodium channel blockers
812013001249101/10/13Pyrimidine derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
822012031620212/13/12Compounds which have activity at m1 receptor and their uses in medicine
832012030972512/06/12Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
842012030978912/06/12Compounds which have activity at m1 receptor and their uses in medicine
852012028854411/15/12Novel retigabine composition
862012027727911/01/12Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions
872012025146810/04/12Compositions comprising alginates with high guluronic acid/mannuronic acid ratio for use in the treatment of dentine hypersensitivity
882012024074209/27/12Novel device
892012024517109/27/12Benzpyrazole derivatives as inhibitors of pi3 kinases
902012023855909/20/12Novel compounds
912012023857109/20/12Indazole derivatives as pi 3-kinase
922012023206109/13/12Novel compounds
932012020774908/16/12Dosing regimen
942012020281108/09/12Novel compounds
952012015744606/21/12Medical use
962012015749106/21/12Muscarinic acetylcholine receptor antagonists
972012015749206/21/12Antibiotic drug
982012014971106/14/12Piperidine derivatives used as orexin antagonists
992012014973106/14/12New medical use
1002012012868905/24/12Anti-il-23 immunoglobulins
1012012012977805/24/12Ligand that bind tgf-beta receptor rii
1022012011464705/10/12 anti-serum album single variable domains
1032012010013704/26/12Immunoglobulins
1042012010108304/26/12S1p1 agonists comprising a bicyclic n-containing ring
1052012010108604/26/12Thiadiazole derivatives and their use for the treatment of disorders mediated by s1p1 receptors
1062012010112404/26/121,2,4-oxadiazol derivatives, their pharmaceutical compositions and their use as sphingosine 1-phosphate 1 receptor agonists
1072012010113404/26/125-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists
1082012010113604/26/125-membered heteroaryl derivatives used as sphingosine 1- phosphate receptor agonists
1092012006517703/15/12Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
1102012005896303/08/12Macrolides with anti-inflammatory activity
1112012004625802/23/12Novel crystalline pharmaceutical product
1122012004646902/23/12Process for the preparation of a biphenyl-2-yl carbamic acid ester
1132012003982002/16/12Antibacterial composition comprising 4-isopropyl-3-methylphenol and zinc ions
1142012004099102/16/123-azabicyclo [4.1.0] heptanes used as orexin antagonists
1152012004102702/16/12Benzimidazoles which have activity at m1 receptor and their uses in medicine
1162012004102802/16/12Benzimidazoles which have activity at m1 receptor and their uses in medicine
1172012003431202/09/124-isopropyl-3-methylphenol for the treatment of inflammation
1182012000632201/12/12Drug dispenser
1192012000422901/05/12Substituted diketopiperazines and their use as oxytocin antagonists
1202011031937112/29/11Pharmaceutical formulations comprising 4-hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
1212011030569212/15/11Antigen-binding contructs
1222011030569312/15/11Anitigen-binding constructs
1232011028809811/24/11Novel compounds
1242011028190911/17/11Substituted quinoline derivatives as h1 receptor antagonists
1252011027565511/10/11Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
1262011027566111/10/11Tricyclic nitrogen compounds used as antibacterials
1272011026973811/03/11Compounds
1282011026997011/03/11Phenethanolamine derivatives for treatment of respiratory diseases
1292011026358810/27/11Tricyclic compounds as glutamate receptor modulators
1302011025375210/20/11Nozzle for a nasal inhaler
1312011025607410/20/11Novel use
1322011024547010/06/11Immunoglobulins
1332011023779209/29/11Quinoline derivatives and their use as 5-ht6 ligands
1342011019027408/04/11Salt of, and processes for the preparation of, 1-isopropyl-4-hexahydro-1h-1,4-diazepine
1352011017806307/21/11Benzpyrazol derivatives as inhibitors of pi3 kinases
1362011016615007/07/11Anhydrous crystal form of ovrepitant maleate
1372011015087106/23/11Treatment of an autoimmune disease using il-18 antagonists
1382011015226206/23/11Novel compounds
1392011014282406/16/11Antibodies against amyloid-beta peptide
1402011014415106/16/11Novel process, salts, composition and use
1412011013569506/09/11Oral dosage form for controlled drug release
1422011013042306/02/11Compounds which have activity at m1 receptor and their uses in medicine
1432011011719005/19/11Pharmaceutical formulations
1442011011826105/19/11Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
1452011006164603/17/11Drug dispenser
1462011006474003/17/11Antigen binding proteins
1472011006572503/17/11Triazole amide derivatives for use in therapy
1482011005916703/10/11Encapsulation of biologically active agents
1492011005997903/10/11Piperidine/cyclohexane carboxamide derivatives for use as vanilloid receptor modulators
1502011004502702/24/11Adjuvant
1512011004613702/24/11Pyrazole derivatives as p2x7 modulators
1522011003452402/10/11Hemi-fumarate salt of a 1,3,4-thiadiazolyl derivative as modulator of the sphingosine 1-phosphate receptor
1532011002157801/27/11Compounds which potentiate the ampa receptor and uses thereof in medicine
1542011000939401/13/11Tricyclic nitrogen compounds and their use as antibacterial agents
1552011000963101/13/11Phenethanolamine derivatives for treatment of respiratory diseases
1562010032999612/30/10Novel combination of therapeutic agents
1572010032402212/23/10Novel compounds
1582010031657912/16/10Novel use of alkyl phosphate esters
1592010031766612/16/10Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss
1602010031767212/16/10Monomaleate monohydrate salt of a 5ht1a receptor antagonist
1612010030808212/09/10Dispensing device
1622010031170612/09/10Method of treatment of allergic rhinitis
1632010031173412/09/10Spiro compounds useful as antagonists of the h1 receptor
1642010030382112/02/10Immunoglobulins
1652010030510712/02/10Quinoline derivatives and their use as 5-ht6 ligands
1662010030512712/02/10Novel compounds
1672010030516612/02/10Novel compounds
1682010029222411/18/10Isothiazolidine 1,1-dioxide and tetrahydro-2h-1,2-thiazine 1,1-dioxide derivatives as p2x7 modulators
1692010029229511/18/105-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators
1702010028615211/11/10N-phenyl hydrazides as modulators of the ghrelin receptor
1712010027590911/04/10Actuator for an inhaler
1722010027385310/28/10Novel isoindol derivatives as ep4 receptor agonists
1732010026769110/21/10Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
1742010026773410/21/10N-[(3,5-dichlorophenyl)methyl]-2-(4-methyl-1-piperazinyl)-2-(1-naphthalenyl)ethanamide as ghrelin receptor modulator
1752010025619910/07/10Crystalline form of an antimalarial compound
1762010025691910/07/10Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
1772010023966609/23/10Process for producing mouldings from (meth) acrylate copolymers by means of injection moulding
1782010022418509/09/10Actuator for an inhaler
1792010022234909/02/10Quinoline derivatives used to treat inflammatory and allergic diseases
1802010021679908/26/10Phthalazine and pyrido[3,4-d]pyridazine compounds as h1 receptor antagonists
1812010021683708/26/10Glycine transport inhibitors
1822010021067208/19/10Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
1832010020325608/12/10Method and apparatus for the application of powder material to substrates
1842010020424208/12/10Piperazine derivative having affinity for the histamine h3 receptor
1852010020427308/12/10Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
1862010019767908/05/10Compounds
1872010019769908/05/10I-oxa-3-azaspiro (4.5) decan-2-one and 1-oxa-3, 8-diazaspiro (4.5) decan-2-one derivatives for the treatment of eating disorders
1882010019076407/29/10Novel compounds
1892010018477007/22/10Compounds
1902010018499607/22/10Process of amide formation
1912010017569807/15/10Capsule
1922010017406507/08/10Compounds
1932010014809106/17/10Method and system for rapid phase luminescense spectroscopy analysis
1942010015219506/17/10Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
1952010014401606/10/10Apparatus for the disruption of animal cells
1962010014475506/10/10Novel compounds
1972010014482906/10/10Novel receptor antagonists and their methods of use
1982010014504006/10/10Benzazepine derivatives for the treatment of neurological disorders
1992010013727606/03/10Compounds which potentiate ampa receptor and uses thereof in medicine
2002010013735306/03/10Tricyclic compounds as antibacterials
2012010013737806/03/10Pyridine compounds for the treatment of prostaglandin mediated diseases
2022010013742806/03/10Oxygen containing heterocycles as glycine transporter inhibiting compounds
2032010013058305/27/10Prolinamide derivatives as modulators of voltage-gated sodium channels
2042010011352105/06/10Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenylpiperidin-3s-yl-)
2052010011352805/06/10Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
2062010011379605/06/10Indole derivatives as s1p1 receptor
2072010010565204/29/10Purines as cysteine protease inhibitors
2082010010568804/29/10Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1
2092010010575404/29/105-(4phenyl)prolinamide for treatment of epilepsy
2102010008742404/08/10Tricyclic nitrogen containing heterocycles as antibacterial agents
2112010008750204/08/10Indazoles used to treat estrogen receptor beta mediated disorders
2122010008766704/08/10Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
2132010008183004/01/10Methods of synthesizing n-hydroxysuccinimidyl carbonates
2142010007595303/25/10Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists
2152010007598203/25/10Pyridinone derivative for the treatment of premature ejaculation
2162010006816603/18/10Oral composition comprising dimethicone copolyol
2172010006940903/18/10"novel compounds"
2182010006941603/18/10Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine d3 receptors
2192010005905203/11/10Sheet driver for use in a drug dispenser
2202010006309703/11/10Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine d3 receptors
2212010005650203/04/10Compounds
2222010005652703/04/10Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
2232010005659503/04/10Pyrazole derivatives as p2x7 modulators
2242010004863902/25/10Oxadiazole derivates as s1p1 receptor agonists
2252010004167202/18/10Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
2262010002969902/04/10Matrix metalloproteinase inhibitors
2272010001628701/21/10Compounds having affinity for dopamine d3 receptor and uses thereof"
2282010001637101/21/10Indole compounds
2292010001002101/14/10Novel compounds
2302010000052801/07/10Manifold for use in medicament dispenser
2312010000052901/07/10Manifold for use in medicament dispenser
2322010000342001/07/10Medicament dispenser
2332010000423001/07/10Azatricyclic compounds and their use
2342010000424001/07/10Indole compounds
2352009032595212/31/09Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2362009032603212/31/09Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2372009031849412/24/09Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2382009031852312/24/09Benzoisoindole derivatives and their use as ep4 receptor agonists
2392009031853012/24/09Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2402009031238812/17/09Benzo [f] isoindoles as ep4 receptor agonists
2412009031254612/17/09Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
2422009030605212/10/09Indenyl derivatives and use thereof for the treatment of neurological disorders
2432009029874212/03/09Process for manufacturing lactose
2442009029114611/26/09Process for manufacturing lactose
2452009029198711/26/09Novel polymorph of (5-amino-6-methoxy-3-pyridincarbonyl) carbamic acid 2-(s)-hydroxymutilin 14-ester
2462009028676211/19/09Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
2472009027560411/05/09M3 muscarinic acetylcholine receptor antagonists
2482009027035510/29/09Compounds
2492009027051010/29/09Glycine transport inhibitors


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Glaxo Group Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glaxo Group Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         


FreshNews promo